SCHEMBL6574174

SCHEMBL6574174

COC(=O)c1cccc(C(O)(C(=O)OC2CC3CCC(C2)[N+]3(C)C)c2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 12/20 0.57
CHRM2 P08172 11/20 0.57
CHRM1 P11229 5/20 0.57
KCNH2 Q12809 5/20 0.57
HRH1 P35367 3/20 0.57
OPRK1 P41145 1/20 0.57
APOBEC3A P31941 1/20 0.56
APOBEC3G Q9HC16 1/20 0.56
CHRM4 P08173 2/20 0.55
CHRM5 P08912 2/20 0.55
CYP2D6 P10635 3/20 0.49
LMNA P02545 2/20 0.49
SLC6A4 P31645 2/20 0.49
CYP2C19 P33261 1/20 0.49
SLC22A1 O15245 1/20 0.48
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6573969 0.83 HTR3E (0.57) CHRM3CHRM2CHRM1KCNH2HRH1
SCHEMBL13526567 0.76 CHRM2 (0.49) CHRM3CHRM2CHRM1KCNH2HRH1
SCHEMBL6574018 0.74 CHRM3 (0.73) CHRM3CHRM2CHRM1CHRM4CHRM5
SCHEMBL29389785 0.73 CHRM3 (0.53) CHRM3CHRM2CHRM1KCNH2HRH1
Flutropium SCHEMBL29388868 0.73 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2HRH1
Tropenziline SCHEMBL29388086 0.73 CHRM3 (0.66) CHRM3CHRM2CHRM1KCNH2HRH1
Flutropium SCHEMBL8290851 0.73 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2HRH1
Trospium SCHEMBL119810 0.73 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2HRH1
Trospium SCHEMBL2447242 0.73 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2HRH1
Trospium SCHEMBL724191 0.73 CHRM3 (1.00) CHRM3CHRM2CHRM1KCNH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383730-A2 ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE Aryx Therapeutics (US) 2004-01-28 EP claimed
WO-2002096855-A2 ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE ARYX THERAPEUTICS (US) 2002-12-05 WO claimed
US-20020169208-A1 Novel anticholinergic compounds and methods of use ARYX THERAPEUTICS 2002-11-14 US claimed
EP-1383730-A2 ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE Aryx Therapeutics (US) 2004-01-28 EP disclosed
WO-2002096855-A2 ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE ARYX THERAPEUTICS (US) 2002-12-05 WO disclosed
US-20020169208-A1 Novel anticholinergic compounds and methods of use ARYX THERAPEUTICS 2002-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169208-A1 Novel anticholinergic compounds and methods of use CHRM3, CHRM5, CHRM2 CHRM3 1/4885CHRM2 3/4885CHRM1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.